Figure 1.
Percentage of TNBC, non-TNBC, and melanoma patients with mutations in the PI3K and MAPK pathways. Mutations in each pathway were identified as somatic genetic variant in at least one gene from the PI3K pathway (PTEN, PIK3CA, AKT1, ERBB2, PIK3R1) or RAS pathway (HRAS, KRAS, NRAS, BRAF, NF1, and SOS1). TNBC, triple-negative breast cancer.